METAGENICS NEUROLIFT

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Buy It Now

Active ingredient:

selenomethionine, Quantity: 125 microgram (Equivalent: selenium, Qty 50 microgram); ademetionine disulfate tosylate, Quantity: 98.04 mg (Equivalent: (S)-S-adenosylmethionine, Qty 50 mg); calcium folinate, Quantity: 270.3 microgram (Equivalent: folinic acid, Qty 250 microgram); Rhodiola rosea, Quantity: 36 mg (Equivalent: Rhodiola rosea, Qty 630 mg); Plectranthus barbatus, Quantity: 16.67 mg (Equivalent: Plectranthus barbatus, Qty 500 mg); potassium iodide, Quantity: 98 microgram (Equivalent: iodine, Qty 75

Available from:

Metagenics (Aust) Pty Ltd

INN (International Name):

ademetionine disulfate tosylate,colecalciferol,Calcium folinate,Hypericum perforatum,Plectranthus barbatus,Potassium iodide,Rhod

Pharmaceutical form:

Tablet, film coated

Composition:

Excipient Ingredients: hyprolose; microcrystalline cellulose; calcium hydrogen phosphate dihydrate; stearic acid; silicon dioxide; calcium stearate; croscarmellose sodium; macrogol 8000; maize starch; calcium phosphate; Acacia; potable water; fractionated coconut oil; dl-alpha-tocopherol; sucrose

Administration route:

Oral

Therapeutic indications:

Maintain/support general health and wellbeing ; Maintain/support healthy thyroid gland function ; Aid/assist thyroid hormone production ; Enhance/promote body adaptation to stress ; Support healthy stress response in the body ; Traditionally used in Ayurvedic medicine to Decrease/reduce/relieve symptoms of stress (Linked Indication:Relieve weariness/tiredness/fatigue/feeling of weakness; Decrease/reduce mental/cognitive fatigue); Decrease/reduce/relieve symptoms of stress (Linked Indication:Relieve weariness/tiredness/fatigue/feeling of weakness; Decrease/reduce mental/cognitive fatigue; Maintain/support mental concentration/focus/clarity); Support healthy emotional/mood balance

Product summary:

Visual Identification: ;

Authorization status:

Listed

Authorization date:

2011-12-12